KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Current Liabilities (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Total Current Liabilities data on record, last reported at $132.2 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 18.6% year-over-year to $132.2 million; the TTM value through Dec 2025 reached $132.2 million, down 18.6%, while the annual FY2025 figure was $132.2 million, 18.6% down from the prior year.
  • Total Current Liabilities reached $132.2 million in Q4 2025 per EBS's latest filing, down from $136.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.2 billion in Q4 2022 and bottomed at $111.9 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $403.4 million, with a median of $365.4 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 228.76% in 2022, then crashed 82.24% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $373.8 million in 2021, then surged by 228.76% to $1.2 billion in 2022, then crashed by 47.0% to $651.3 million in 2023, then plummeted by 75.07% to $162.4 million in 2024, then fell by 18.6% to $132.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $132.2 million in Q4 2025, $136.5 million in Q3 2025, and $127.1 million in Q2 2025.